Here's a quote from the 2009 journal article:In a recent study published in the journal Environmental Health Perspectives, U.S. researchers sampled a small portion of pills on the market—medicines for conditions ranging from acid reflux, infections, and inflammation to ulcerative colitis and high blood pressure, among others—and found that 10 to 20 percent contained two types of plasticizing chemicals tied to lifelong health problems. These plastic chemicals, known as phthalates, are often found in vinyl flooring and shower curtains, cleaning products, nail polish, perfumes, and fragranced personal care products, insecticides, and food packaging.
http://ehp03.niehs.nih.gov/article/fetc ... p.117-a74aThe 2004 case study pinpointed Asacol®, a medication for treating ulcerative colitis, as a probable source of phthalate exposure. Asacol is covered with an enteric coating of dibutyl phthalate (DBP) that prevents the medication from degrading before it reaches the small intestine. Concentrations of the main metabolite of DBP in the urine of the case study subject corresponded to an uptake of DBP exceeding by two orders of magnitude the 95th percentile reported by the Centers for Disease Control and Prevention in the general population. The concentrations also surpassed the reference dose established for DBP by the U.S. Environmental Protection Agency (EPA) on the basis of animal testing.
To assess possible links between phthalate-containing prescription medication usage and excreted metabolites, the investigators searched National Health and Nutrition Examination Survey (NHANES) data from survey periods between 1999 and 2004 when urine samples were tested for phthalate metabolites and participants were asked about their use of prescription medications. Various enteric-coated medications identified as likely to contain phthalates included mesalamine (the generic form of Asacol), didanosine (an antiretroviral agent), omeprazole (which inhibits gastric acid secretion), and theophylline (used to treat asthma and other lung diseases).
Among the 6 documented mesalamine users, average urine concentrations of DBP metabolites were 50 times higher than those of nonusers. For 2 of the 6 mesalamine users, the DBP metabolite concentrations pointed to uptake exceeding the EPA’s reference dose.
http://www.rodale.com/drugs-inactive-ingredients
From the same website, here's a nice overview about the potential toxicity of wheat, with the author of "Wheat Belly"
http://www.rodale.com/wheat-free-diet-0 ... heatfarcry